Innate Pharma price target raised to $10 from $9 at SVB Securities

SVB Securities analyst Daina Graybosch raised the firm’s price target on Innate Pharma (IPHA) to $10 from $9 and keeps an Outperform rating on the shares. SVB Securities is "pleased" by the partnership with Takeda (TAK) to develop ADCs for Celiac disease, the analyst tells investors in a research note.